Blood testing at your finger tips. Know Now. No waiting. A pocket laboratory for the 21 st century

Transcription

1 Blood testing at your finger tips. Know Now. No waiting. A pocket laboratory for the 21 st century 1

2 Blood testing is a huge global high growth market Driving Market Growth: $51.8 billion $60.6 billion Chronic diseases such as diabetes increasing Populations aging Governments & Insurance companies trying to minimise hospital stays Testing frequency increasing to manage chronic conditions 2

3 Current players are wedded to expensive, slow, big box technology (cf. IBM) Attomarker is going to put a laboratory in the hands of every doctor, pharmacist and consumer (cf. Apple) Know now, no waiting 3

4 Attomarker USPs A pocket laboratory giving high quality results in five minutes from a pin-prick of blood 1 Results in five minutes. Know now, no waiting. - Currently, time to results is hours to days - Diagnostic accuracy of RTI vs Pneumonia increases by 25% when you know now. Can be operated by anyone - Currently, blood tests are performed by a health care professional in a clinic or hospital Requires a tiny pin-prick of blood. No syringe, no pain, no stress - Currently, venous blood draw volumes are typically 2.7 ml to 6.0 ml - Good for young, old and needle phobic. Our device is 1/6 th cost of the nearest competitor - Attomarker is affordable and accessible. Everyone gets quality care. 4 3 Hand-held, so perfect for point-of-care. Every doctor, pharmacist and consumer can have one 4

5 Our Nearest Competitor Abbott i-stat Vs. Attomarker M device Blood drawn from arm One test per chip Test price: Operated by healthcare professional Emergency department focused Connectivity to patient record via 1000 add on 800 device Blood from finger-prick Multiple tests per chip Test price Operated by anyone Consumer focused Global connectivity via iphone Genalyte, Athelas, Orphidia and NowDiagnostics have been said to be heirs apparent to Theranos. Abbott s i-stat is the current market leader. 5

6 Launch Tests Food Allergies The incidence of food allergies is growing. 7m European adults and 3m children suffer. In N. America, figures are 12m adults & 4.4m children. Government provision of allergy services is low. Allergy testing in private doctors is expensive. Cheapest in London is over 100. Result is a large pent-up unmet need, especially for concerned parents of young children. A pharmacist test would be highly demanded Total addressable markets* UK DW** 900m 8bn C-Reactive Protein C-reactive protein (CRP) is a blood plasma biomarker for inflammation, whose concentration increases or decreases in response to inflammation. The UK is not reducing antibiotic prescription rates with statistical significance whilst antimicrobial resistance (AMR) is increasing. AMR increases the cost of healthcare with lengthier hospital stays and more intensive care required. CRP testing at the pharmacy or in general practice, following NICE guidelines for CRP testing for RTI and Pneumonia with associated symptoms, could reduce antibiotic prescription rates and combat AMR. 0.9m 7.8m Pregnancy A $1.2b growth market, growing because women are having children later. Current urine-based tests are only 80% accurate in the hands of the user. Many women in our research said they thought current methods were seriously old-fashioned and undignified. Attomarker will give an accurate result from a pin-prick of blood at the pharmacist - telling them within a date range when they became pregnant. 11.4m 100m *One test per every appropriate individual per year **Developed World 6

7 A Launch Care Pathway Example Food Allergy at the GP or Pharmacist A pin-prick blood test no need for phlebotomist. An IgE blood test for the top 8 food allergens with results in 5 minutes. Results presented as a RAST profile. A clinically verified interpretation of allergy. Explain the RAST profile in reference to allergy guidelines. Demonstrate the Attomarker Allergy app that can be used to deliver allergy alerts via a food barcode scanner 15 minute consultation One consultation. One test. Continued care. 7

8 A Future Care Pathway Example Fatty Liver / Type 2 Diabetes at the GP or Pharmacist A pin-prick blood test no need for phlebotomist Full liver function tests results available within 5 minutes Interpret results in reference to clinically validated guidelines 15 minute consultation Suggest measurable lifestyle changes, monitored by the Attomarker App and interact with your healthy living community. Re-schedule test to check progress Multiple consultations. Multiple tests. Continued care. Care pathway to be optimised prior to launch in consultation with diabetes specialists. A full risk analysis will be performed. 8

9 Attomarker Future Test Portfolio Ensuring a continued and growing revenue stream whilst tacking high impact problems. Fatty Liver Type 2 Diabetes 5 th Generation HIV Indoor Allergens Outdoor Allergens Sepsis 3bn 3bn 7bn 7bn 2bn Prostate Cancer Type 1 Diabetes Nut Allergens Food Allergens I, II, III Hepatitis A, B, C 2bn 150m 7bn 7bn 3.6bn Emergency Room Chip Flu Test Wellness Panel Alzheimer s Test Immunotherapy Cohort surveillance 3.2bn 1.9bn 0.5bn 10bn 1.1bn? Market size 9

10 Routes to Market Private Healthcare Pharmacies Consumer Premium product launch Not price-sensitive MoU with leading company to access up to 10,000 GPs in the UK In discussion with largest independent provider of laboratory diagnostics Preliminary discussion with a group of world class private hospitals MoU signed with a Malaysian pharmacy chain MoU Signed with a major global wholesaler and supplier for an initial roll out to 500 stores Aim to launch via Apple (EU) Healthcare Potential to launch at high footfall stores Potential to hold a Today at Apple event Estimated that there are 1m early adopters 10

11 Funding Previous funds 5m in Research Grants RCUK, BBSRC, EPSRC, EU, Innovate UK. 500K Seed Funding, 2.5m Series A Funding British Innovation Fund Prototype milestone achieved in 99 days Required Funds 15m Series B funding required. This our last equity funding round and so new investors will not be diluted. We will be EBIDTA positive by Q Series B 15m 3m Production capacity for 10k devices/year 4m OpEx marketing, inventory, CE marking launch, software, staff growth 8m Production capacity for 1m chips/year 11

12 The Attomarker Team Board Members Roger Killen NED David Miller CMO Andrew Shaw CEO Nigel Clarke Chairman Exeter Scientist Team 4 team members with a combined total experience of 40+ years Production Consortium Griff Williams Investment Director 30+ German engineers, scientists and software engineers. Outsourced production reduces costs whilst increasing efficiency and peer review. Data Security Software Software Core IP JV established Cartridge manufacturer Device Manufacturer 12

13 Additional Information 13

14 14

15 15

16 FDA evaluation protocol: Preliminary study passes FDA requirements 16

17 Epidemic Monitoring Attomarker has real strength in its combination of technologies, all in one package. Attomarker can leverage its connectivity to geolocate test results, presenting them on a disease heatmap. This screening portfolio could tackle our biggest threats (Ebola, Dengue, Tuberculosis) Test results are automatically stored in a cloud data room meaning that that disease outbreaks can be monitored in real-time from one, centralized location. This is a game changer. Currently, governmental bodies have to communicate the incidence of disease as they become aware. This is a slow process. Attomarker would be a predictor of disease outbreaks 17

18 Big Data and Artificial Intelligence Rather than robots, AI for healthcare is about clever algorithms and the correct software to implement them When Attomarker reaches its target of 1m consumer devices, we will be generating the largest and highest quality data set of personal healthcare information AI will gain insight from this data to aid in diagnosis. It has the capability to look for trends, analyze large data sets and recognize key markers for early intervention in the absence of a healthcare professional When AI informs you of a possible diagnosis and identifies the best next step, we are answering the what next? question for the consumer 18

19 Intellectual Property 19

20 20